Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure

Ovid Technologies (Wolters Kluwer Health) - Tập 111 Số 19 - Trang 2454-2460 - 2005
Liviu Klein1, Christopher M. O’Connor1, Jeffrey D. Leimberger1, Wendy Gattis‐Stough1, Ileana L. Piña1, G. Michael Felker1, Kirkwood F. Adams1, Robert M. Califf1, Mihai Gheorghiade1
1From Northwestern University Feinberg School of Medicine (L.K., M.G.), Chicago, Ill; Duke Clinical Research Institute (C.M.O., J.D.L., W.G.-S., G.M.F., R.M.C.), Durham, NC; Case Western Reserve University (I.L.P.), Cleveland, Ohio; and University of North Carolina (K.F.A.), Chapel Hill, NC.

Tóm tắt

Background— The prognostic value of serum sodium in patients hospitalized for worsening heart failure has not been well defined. Methods and Results— The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy. In a retrospective analysis, we investigated the relationship between admission serum sodium and the primary end point of days hospitalized for cardiovascular causes within 60 days of randomization, as well as the secondary end points of in-hospital mortality, 60-day mortality, and 60-day mortality/rehospitalization. The number of days hospitalized for cardiovascular causes was higher in the lowest sodium quartile: 8.0 (4.5, 18.5) versus 6 (4, 13) versus 6 (4, 11.5) versus 6 (4, 12) days ( P <0.015 for comparison with the lowest quartile). Lower serum sodium was associated with higher in-hospital and 60-day mortality: 5.9% versus 1% versus 2.3% versus 2.3% ( P <0.015) and 15.9% versus 6.4% versus 7.8% versus 7% ( P =0.002), respectively. There was a trend toward higher mortality/rehospitalization for patients who were in the lowest sodium quartile. Multivariable-adjusted Cox proportional hazards analysis showed that serum sodium on admission, when modeled linearly, predicted increased 60-day mortality: sodium (per 3-mEq/L decrease) had a hazard ratio of 1.18 with a 95% CI of 1.03 to 1.36 ( P =0.018). Conclusions— In patients hospitalized for worsening heart failure, admission serum sodium is an independent predictor of increased number of days hospitalized for cardiovascular causes and increased mortality within 60 days of discharge.

Từ khóa


Tài liệu tham khảo

10.1001/jama.287.12.1541

Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002; 287: 1531–1540.

10.1016/S0140-6736(02)09455-2

10.1016/j.jacc.2003.12.040

10.1161/01.cir.0000035653.72855.bf

10.1067/mhj.2003.150

10.1016/S0735-1097(02)02490-7

10.1016/S0002-8703(00)90303-X

10.1016/S0002-9149(03)00740-9

10.1001/jama.290.19.2581

10.1016/j.amjcard.2003.09.013

10.1016/j.amjcard.2003.12.011

10.1016/j.amjmed.2003.11.014

10.1016/j.cardfail.2004.02.011

10.1056/NEJM199908193410806

10.1172/JCI107207

Schrier RW, Berl T, Anderson RJ. Osmotic and non-osmotic control of vasopressin release. Am J Physiol. 1979; 236: F321–F332.

10.1016/S0735-1097(83)80040-0

10.1016/0002-9149(86)90065-2

10.1056/NEJM198402093100603

10.1210/jcem-59-5-924

10.1038/ki.1987.156

10.1161/circ.63.3.7006851

10.1016/0002-9343(65)90211-1

10.1136/hrt.47.2.161

10.1067/mhj.2002.119608

Dargie HJ, Cleland JG, Leckie BJ, Inglis CG, East BW, Ford I. Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation. 1987; 75 (suppl IV): 98–107.

10.1016/0002-9149(93)90220-7

10.1001/archinte.1996.00440150068007

10.1016/S0735-1097(84)80364-2

10.1016/S0735-1097(87)80278-4

10.1161/circ.73.2.3002660

Bankir LT, Trinh-Trang-Tan MM. Renal urea transporters: direct and indirect regulation by vasopressin. Exp Physiol. 2000; 85: 243S–252S.

10.1016/S0735-1097(87)80223-1

10.1016/S0002-9149(97)00284-1

10.1016/S0002-8703(98)70352-7

10.1161/01.cir.0000070422.41439.04

10.1001/jama.291.16.1963

10.1016/j.ahj.2004.08.005

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 111 Số 19

2454-2460

Thông tin tác giả